BDTX-189 is an Orally Active Inhibitor of Allosteric EGFR and HER2 Oncogenic Mutations
Epidermal growth factor receptor (EGFR) is a growth-factor-receptor tyrosine kinase. Elevated levels of the EGFR, and/or its cognate ligands act as a common component of multiple cancer types and appear to promote solid tumor growth. BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations....